Kuching tops Sarawak HIV cases for 5th year as 74 recorded in 2024
KUCHING (July 17): Sarawak recorded 217 new human immunodeficiency virus (HIV) cases in 2024, with Kuching, Bintulu and Miri collectively accounting for over 66 per cent of the state's total, said deputy Health Minister, Dato Lukanisman Awang Sauni.
Kuching alone reported 74 new cases (34.1 per cent) in 2024 – marking the fifth consecutive year it has led in new infections – followed by Bintulu with 36 cases (16.6 per cent) and Miri with 35 cases (16.1 per cent).
Between 2020 and 2024, Kuching's annual figures were 87, 120, 85, 70 and 74, respectively.
'Although new HIV infections in Sarawak fell from 248 in 2023 to 217 in 2024, the overall infection rate remains a cause for concern,' said Lukanisman.
He made these remarks during a press conference after officiating at the Asean Regional Dialogue on Affordable ARV Drugs and Community-Based Testing (CBT), held at a hotel here yesterday.
He noted that between 2019 and 2023, Sarawak consistently reported between 226 and 248 cases annually, with 2023 recording the highest rate at 9.88 cases per 100,000 population.
As of mid-2025, the state has already recorded 106 new cases.
'If the trend continues, this year's total will likely mirror last year's figure,' he added.
Nationwide, Malaysia has halved new HIV infections since 2010, but still falls short of the United Nations' 95-95-95 targets, which aim for 95 per cent of people living with HIV to know their status, 95 per cent of those diagnosed to receive treatment, and 95 per cent of those on treatment to achieve viral suppression.
'Today, Malaysia has achieved 64 per cent in diagnosis, 94 per cent in treatment, and 93 per cent in viral suppression.
'While we have made progress, there is still a gap that needs to be addressed,' Lukanisman said.
Moreover, based on data collected by the authorities, he expressed concern over the increasing number of infections among men under 40, with 76 per cent of last year's new cases nationwide linked to high-risk sexual behaviour.
'The emergence of this demographic trend is alarming, thus, we must rethink our strategies to reach this younger population more effectively,' he said.
Lukanisman also stressed that the issue can only be addressed if high-risk groups are willing to come forward for testing.
'We are now promoting community-based testing led by the private sector so that individuals can undergo screening in familiar and trusted environments,' he explained.
He also reiterated his call for high-risk groups to actively participate in the Ministry of Health's (MoH) community-based testing initiatives, especially through non-governmental organisations (NGOs) and trusted networks, to ensure more people can access testing and begin treatment in safe, non-discriminatory settings.
Present at the event were the Patron of the Malaysian AIDS Foundation Borneo Datin Patinggi Datuk Amar Jamilah Anu; Deputy Director General of Public Health Dr Ismuni Bohari; and the State Director of Health Dr Veronica Lugah. HIV Kuching Lukanisman Awang Sauni
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
2 hours ago
- The Sun
Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone
HONG KONG SAR - Media OutReach Newswire - 30 July 2025 - The Greater Bay Area International Clinical Trial Institute of Hong Kong ('GBAICTI'), the Greater Bay Area International Clinical Trials Center of Shenzhen ('BAY TRIAL'), Immuno Cure BioTech ('Immuno Cure') in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding ('MOU') in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area ('GBA'), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen. GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform ('Platform') by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong. Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: 'The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.' Dr. LI Yichong, Director of BAY TRIAL, said: 'This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area's pharmaceutical and medical device industry.' Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy ('ART') can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host's immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure's ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART. Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People's Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People's Hospital, Tianjin Second People's Hospital, The Sixth People's Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center. Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: 'We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure's therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.' GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national 'Healthy China' strategic goals.
The Sun
4 hours ago
- The Sun
MOH prioritises education in medicine price display enforcement amid legal challenge
PUTRAJAYA: The Ministry of Health (MOH) remains committed to an educational approach in enforcing the Price Control and Anti-Profiteering (Medicine Price Labelling) Order 2025, even as a judicial review application challenges the regulation. Health Minister Datuk Seri Dr Dzulkefly Ahmad emphasized that while the ministry respects the legal process, it will proceed with awareness initiatives to avoid gaps in enforcement. 'We will continue with this approach to avoid enforcement gaps while the court process is ongoing,' he said after officiating the 2025 National Health Technology Assessment Conference and the 30th anniversary of the Malaysian Health Technology Assessment Section (MaHTAS). The regulation, effective since May 1, requires private clinics and community pharmacies to display medicine prices on shelves, in catalogues, or through written price lists. The move aims to enhance transparency and prevent profiteering in the healthcare sector. Dr Dzulkefly addressed reports that the Malaysian Medical Association (MMA) and seven other organisations, including the Sabah Private Practitioners Association (APPS) and the Malaysian Muslim Doctors Association (PERDIM), have sought leave for a judicial review. On May 4, the minister clarified that no fines or penalties would be imposed during the initial three-month grace period, prioritizing stakeholder education instead. With the grace period ending on July 31, neither MOH nor the Ministry of Domestic Trade and Cost of Living (KPDN) has announced an extension. - Bernama
New Straits Times
5 hours ago
- New Straits Times
Govt fine-tuning legal framework to curb rising private healthcare costs
KUALA LUMPUR: The government is reviewing existing legislation, including an amendment to the Private Healthcare Facilities and Services Act 1998 (Act 586), to support the implementation of the Reset strategy aimed at curbing private healthcare inflation. Finance Minister Datuk Seri Anwar Ibrahim said the Ministry of Health (MOH) is refining the legal framework to enable initiatives under Reset, including the introduction of the Diagnosis-Related Group (DRG) payment system. "The MOH is currently reviewing relevant acts to align efforts to address medical inflation. Amendments to the Private Healthcare Facilities and Services Act 1998 are being studied and refined to allow for the implementation of the DRG payment system, which will require the sharing of minimum clinical and financial data, as well as other related initiatives under the Reset strategic framework. "The government will continue to consider amendments to other acts under the ministry's jurisdiction, if necessary, to empower the overall Reset strategy," he said in a written parliamentary reply. Anwar, who is also prime minister, said the Reset strategy comprises five strategic pillars and 11 key initiatives. The first pillar is the improvement of Medical and Health Insurance and Takaful (MHIT) through the development of a basic MHIT product that will modify MHIT product features and enable the setting of more sustainable and stable premium rates in the long term. He said the second pillar is increasing price transparency through the display of medicine prices and the publication of price ranges for common healthcare services to enable consumers to make informed decisions. "Third, strengthening the digital health ecosystem through electronic medical records to improve quality of care and reduce the need for repeated diagnostic tests. "Additionally, expanding cost-effective options through Rakan KKM and the provision of more affordable hospitals, including encouraging the expansion of non-profit hospitals. "Lastly, transforming the provider payment mechanism to a DRG system to ensure value-based healthcare payments that align with the interests of patients, healthcare providers, and payers," he said. He added that the implementation of Reset initiatives is monitored by the Joint Ministerial Committee on Private Healthcare Costs (JBMKKS), co-chaired by Finance Minister II Datuk Seri Amir Hamzah Azizan and Health Minister Datuk Seri Dr Dzulkefly Ahmad. He was responding to Sim Tze Tzin (PH-Bayan Baru) on the Reset strategy to address medical inflation.
